Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Published:2018-05 Issue:3 Volume:19 Page:e335-e348
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Khunger Monica,Jain Prantesh,Rakshit Sagar,Pasupuleti Vinay,Hernandez Adrian V.,Stevenson James,Pennell Nathan A.,Velcheti Vamsidhar

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer;Reck;N Engl J Med,2016

2. NSCLC, metastaticCheckMate 026: a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC;Socinski;Ann Oncol,2016

3. Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: safety, clinical activity, and PD-L1 expression;Verschraegen;J Clin Oncol,2016

4. Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non–small-cell lung cancer;Antonia;J Clin Oncol,2016

5. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers;Carbognin;PLoS One,2015

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive evaluation of PD-1 inhibitors marketed in China based on a Quick Guideline for drug evaluation and selection in Chinese Medical Institutions (second edition);Intelligent Pharmacy;2024-08

2. Immunotherapy-induced hepatitis in metastatic colorectal cancer: a systematic review and meta-analysis;Baylor University Medical Center Proceedings;2024-07-08

3. Immunotherapy-induced colitis in metastatic colorectal cancer: a systematic review and meta-analysis;Baylor University Medical Center Proceedings;2024-04-25

4. Overexpression of MTFR1 promotes cancer progression and drug-resistance on cisplatin and is related to the immune microenvironment in lung adenocarcinoma;Aging;2024-01-02

5. Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients;ESMO Open;2023-12